Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 11Lymphoid 10Myeloid 3Sarcoma 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1349Leukemia, Myeloid, Acute 1133Leukemia, Myelogenous, Chronic, BCR-ABL Positive 713Leukemia 675Precursor Cell Lymphoblastic Leukemia-Lymphoma 646Myeloproliferative Disorders 527Leukemia, Myelomonocytic, Chronic 424Lymphoma, Non-Hodgkin 407Primary Myelofibrosis 384Multiple Myeloma 369Leukemia, Lymphocytic, Chronic, B-Cell 367Hodgkin Disease 348Leukemia, Myeloid, Chronic-Phase 304Lymphoma 291Blast Crisis 256Leukemia, Myeloid, Accelerated Phase 238Lymphoma, Mantle-Cell 231Lymphoma, Follicular 226Burkitt Lymphoma 224Polycythemia Vera 222Lymphoma, Large B-Cell, Diffuse 219Lymphoma, B-Cell, Marginal Zone 203Congenital Abnormalities 192Anemia, Refractory, with Excess of Blasts 187Lymphoma, Large-Cell, Immunoblastic 182Myelodysplastic-Myeloproliferative Diseases 175Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 173Thrombocythemia, Essential 167Neoplasms, Plasma Cell 161Hematologic Neoplasms 161

Interventions

sonidegib 1ruxolitinib 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Hemorrhagic Disorders × Myeloid × Clear all
NCT02055781 2021-11-18

PAC326

CTI BioPharma

Phase 3 Terminated
311 enrolled 12 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sierra Oncology LLC - a GSK company

Phase 2 Terminated
39 enrolled
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡